BeigelJHTomashekKMDoddLE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. Epub ahead of print 22May2020. DOI: 10.1056/NEJMoa2007764.
2.
ThorlundKDronLParkJ, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health. Epub ahead of print 24April2020. DOI: 10.1016/S2589-7500(20)30086.
3.
SchoenfeldD. Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. Crit Care2006; 10(1): 103.
4.
CummingsMJBaldwinMRAbramsD, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet2020; 395(10239): 1763–1770.
5.
AnnaneDSébilleVCharpentierC, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA2002; 288(7): 862–871.
6.
NavaSAmbrosinoNCliniE, et al. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. Ann Intern Med1998; 128(9): 721–728.
7.
CruzDNAntonelliMFumagalliR, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA2009; 301(23): 2445–2452.
8.
AmaralAPolymyxinB. Hemoperfusion and mortality in abdominal septic shock (Letter to the editor). JAMA2009; 302(18): 1968–1969.
9.
PayenDMGuilhotJLauneyY, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med2015; 41(6): 975–984.
